Humanigen, Inc

Company Listings from SPi: Humanigen, Inc

You are here: Home >> SPi Company Listings >> Humanigen, Inc

 

Humanigen, Inc

Website:
http://

Search for other references to "humanigen" on SPi News

Latest Humanigen, Inc News

Humanigen Announces Preliminary Results From Ifabotuzumab Phase I Study Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting BURLINGAME, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”), a biopharmaceutical company developing its portfolio of Humaneered® monoclonal anti...... 13:00 GMT Monday 1st April 2019

Humanigen Data Presented at the 2019 National Comprehensive Cancer Network (NCCN) Annual Conference Demonstrates Potential to Improve the Efficacy of CAR-T Therapy BURLINGAME, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered®...... 21:00 GMT Thursday 21st March 2019

Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Accepted as Oral Presentation at the 2019 Transplantation & Cellular Therapy (TCT) Annual Meeting BURLINGAME, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered®...... 13:00 GMT Monday 25th February 2019

Humanigen Study of GM-CSF Neutralization With CAR-T Therapy Selected for Front Cover of Current Edition of ‘blood’®, The Official Journal of the American Society of Hematology (ASH) BURLINGAME, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”) announced today that the editors of ‘blood’, which is widely regarded as a premier jo...... 13:00 GMT Friday 15th February 2019

Humanigen Announces Publication Demonstrating EphA3 Receptor as an Attractive Antibody Target for Brain Cancer and Other Solid Tumor Therapy in the Journal ‘Cancers’ BURLINGAME, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”), a biopharmaceutical company developing its portfolio of Humaneered® monoclonal antib...... 21:05 GMT Thursday 3rd January 2019

Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH) BURLINGAME, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”), a biopharmaceutical company focused on the development of its proprietary Humaneered mon...... 12:30 GMT Tuesday 4th December 2018

Lenzilumab Study Published in ‘blood’, the Official Journal of the American Society of Hematology (ASH), First Edition BURLINGAME, Calif., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”), a biopharmaceutical company focused on the development of its proprietary Humaneered mon...... 12:30 GMT Friday 30th November 2018

Humanigen Announces Lenzilumab Study Results Accepted as Oral Presentation at the 2018 Annual Meeting of the American Society of Hematology (ASH) BURLINGAME, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”), a biopharmaceutical company developing its portfolio of Humaneered monoclonal antibodies...... 12:00 GMT Friday 2nd November 2018

Humanigen Announces Positive Topline Study Results BURLINGAME, Calif., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc., (“Humanigen”), a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology trea...... 13:00 GMT Monday 20th August 2018

Humanigen CEO to Present at 8th Annual LD Micro Invitational BURLINGAME, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- (OTCQB:HGEN), a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments, today announc...... 13:00 GMT Wednesday 30th May 2018

Buy Humanigen, Inc
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us